What is JBIO's software and technology licenses, net?

JBIO (JBIO) reported software and technology licenses, net of $69K in Q1 2026.

What is the long-term trend for JBIO's software and technology licenses, net?

Over 4 years (2021 to 2025), JBIO's software and technology licenses, net has grown at a -30.9% compound annual growth rate (CAGR), from $302K to $69K.

JBIO JBIO Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Vertex PharmaceuticalsVRTX

——

Travere Therapeutics, Inc.TVTX

——

Vera TherapeuticsVERA

——

AnaptysBio, Inc.ANAB

——

Cullinan Therapeutics, Inc.CGEM

——

Vor BiopharmaVOR

——

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's software and technology licenses, net?: JBIO (JBIO) reported software and technology licenses, net of $69K in Q1 2026.
What is the long-term trend for JBIO's software and technology licenses, net?: Over 4 years (2021 to 2025), JBIO's software and technology licenses, net has grown at a -30.9% compound annual growth rate (CAGR), from $302K to $69K.